EU agency recalls Pacira drug on contamination worries
LONDON (Reuters) - The European Medicines Agency said on Friday it had recommended cancer drug DepoCyte be recalled in Europe, where suitable alternative treatments are available, due to sterility concerns at a U.S. plant operated by Pacira Pharmaceuticals.
A recent inspection carried out jointly by France and Britain at Pacira's manufacturing site in San Diego identified a number of manufacturing deficiencies related to a lack of adequate sterility assurance in the manufacturing process.
The agency said there was no evidence at present of any microbial contamination of products on the market or risk to patients and the recall was a precautionary measure.
(Reporting by Ben Hirschler; Editing by Helen Massy-Beresford)
- First Ebola victim in Sierra Leone capital on the run
- Former WWE champ nabs suspected burglar in Arizona
- Apple iPhones allow extraction of deep personal data, researcher finds
- EU edges to economic sanctions on Russia but narrows scope |
- China's Guangdong province removes over 850 'naked officials' from their posts
Robert Blendon of the Harvard School of Public Health says the Affordable Care Act's unpopularity in 12 key states will keep it a central issue in the 2014 elections. Video